文献速递肺外科

异时性第二原发肺癌的肺叶切除与亚肺叶切除比较:一项倾向性评分研究

Lobectomy Versus Sublobectomy in Metachronous Second Primary Lung Cancer: A Propensity Score Study.
PubMed 文献 · Ann Thorac Surg · 2018-05-28

基于监测、流行病学和最终结果数据库的回顾性研究,纳入1392例异时性第二原发肺癌患者,倾向性评分匹配454对,比较肺叶切除与亚肺叶切除的生存结局。肺叶切除与显著更好的生存相关(p=0.023),亚肺叶切除在肿瘤≤2 cm时显示等效性。

要点

  • 肺叶切除与异时性第二原发肺癌显著更好的生存相关(p=0.023)。
  • 亚肺叶切除在肿瘤≤2 cm时与肺叶切除生存相当。
  • 初始I期患者肺叶切除预后更优,初始III期患者亚肺叶切除有优势。

核心结论

  • 肺叶切除仍是异时性第二原发肺癌的有效选择。
  • 亚肺叶切除在肿瘤≤2 cm时有价值且显示等效性。
  • 对于晚期疾病或高风险患者,需要额外研究探索亚肺叶切除的价值。

研究设计与样本

  • 基于监测、流行病学和最终结果数据库的回顾性研究。
  • 采用倾向性评分匹配减少第一和第二肺癌临床病理特征差异导致的潜在偏倚。
  • 识别1392例异时性第二原发肺癌患者,匹配454对。
  • 评估肺叶切除与亚肺叶切除的效果并进行亚组分析。

主要发现

  • 肺叶切除与显著更好的生存相关(p=0.023)。
  • 亚组分析显示,若既往肺癌为I期,肺叶切除获得显著更好的预后;而初始III期癌症患者中亚肺叶切除有优势。
  • N0疾病患者肺叶切除预后显著更好,但N1或N2无此优势。
  • 按肿瘤大小分层,肿瘤≤1 cm时亚肺叶切除预后与肺叶切除相当。
  • 肿瘤1至2 cm时肺叶切除与更好生存相关但无统计学显著性;肿瘤2至3 cm时肺叶切除 confer 显著更好生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal surgical approach for metachronous second primary lung cancer (MSPLC) has not been well established yet. In this study, survival outcome of lobectomy was compared with sublobectomy for MSPLC. METHODS: A retrospective study was conducted based on the Surveillance, Epidemiology, and End Results database. Propensity score matching was used to reduce the potential bias caused by the variance of the clinicopathologic features of the first and second lung cancer. The effect of lobectomy and sublobectomy for MSPLC was assessed and explored in subgroup analyses. RESULTS: We identified 1,392 MSPLC patients, and 454 pairs of patients were matched. Lobectomy was associated with a significantly better survival (p = 0.023). Subgroup analyses showed that lobectomy achieved a significantly better prognosis if previous lung cancer was stage I, whereas sublobectomy had advantages in patients with initial stage III cancer. Moreover, patients with lobectomy had a significantly better prognosis in N0 disease but not in N1 or N2. Stratified by tumor size, the prognosis of sublobectomy was comparable to lobectomy for tumors sized 1 cm or smaller. Lobectomy was associated with a better survival in tumors sized 1 to 2 cm, although without statistical significance. For tumors sized 2 to 3 cm, lobectomy conferred a significantly better survival. CONCLUSIONS: This study indicates that lobectomy is still a valid choice for MSPLC. Sublobectomy has value and shows equivalency in tumors sized 2 cm or smaller. For patients with advanced disease or at high risk, additional studies are needed to explore the value of sublobectomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Yang X, Zhan C, Li M, et al. Lobectomy Versus Sublobectomy in Metachronous Second Primary Lung Cancer: A Propensity Score Study. Ann Thorac Surg. 2018. PMID: 29852145. doi:10.1016/j.athoracsur.2018.04.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。